A new twist to menopausal hormone replacement dilemma
Sept. 12, 2017
| Sabin Russell / Fred Hutch News Service
New follow-up research to a landmark study on menopausal hormone replacement therapy has found that women assigned to those drugs on the study had no higher risk of death than women who took a placebo.
A new algorithm created by Dr. Philip Bradley and colleagues could aid the development of tools to decode T-cell receptor sequences and, ultimately, improve the diagnosis and treatment of cancers, reported this week in Nature.
Dr. Katherine A. Guthrie, a biostatistician in the Public Health Sciences Division at Fred Hutch, is co-leading a $7 million grant that includes a multicenter clinical trial that will compare popular treatments for menopause-related vaginal symptoms ranging from dryness and atrophy (thinning and shrinking of the tissues) to itching, irritation and painful intercourse.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.